Corcept Therapeutics President of Oncology Exercises Options and Sells Shares Under 10b5-1 Plan

Overview

On October 5, 2026, Roberto Wandenkolk Vieira, President of Oncology at Corcept Therapeutics Inc ($CORT), reported the exercise of stock options and the subsequent sale of 8,333 shares of common stock executed on October 2, 2026.

Transaction Details

• Option Exercise: Mr. Vieira exercised 8,333 stock options with an exercise price of $21.63 per share, with an expiration date of February 1, 2034.
• Open Market Sales: All 8,333 acquired shares were sold in three tranches:
  • 1,100 shares at a weighted average price of $114.5205 (range: $114.03 – $114.90)
  • 2,086 shares at a weighted average price of $115.7298 (range: $115.16 – $116.04)
  • 5,147 shares at a weighted average price of $116.5850 (range: $116.24 – $117.22)
• Gross Proceeds: Total sale proceeds amounted to approximately $967,448, generating a net pre-tax gain of approximately $787,205 above the $180,243 aggregate exercise cost.

Plan and Holdings

• Rule 10b5-1 Plan: The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 17, 2026, prior to his appointment as an officer.
• Post-Transaction Holdings: Mr. Vieira directly holds 3,946 shares of common stock (including unvested restricted stock awards) and 133,334 unexercised stock options.

Market Impact & Significance

The filing represents a standard exercise-and-sell transaction governed by a Rule 10b5-1 trading plan. Given that the sales were fully matched to option exercises and executed pursuant to a pre-established plan, the trading significance is categorized as Low.